Abstract
Adalimumab belongs to the group of tumour-necrotizing factor alpha inhibitors (TNFα) that has been widely used in the therapy of chronic inflammatory rheumatic diseases, and subsequently, the indications are still incorporating more fields (gastroenterology, dermatology and ophthalmology). Adalimumab became a standard part of treatment for patients with rheumatoid arthritis but also a reference drug in many studies with new biologics.
This review aims to present adalimumab as a treatment for inflammatory diseases of movement apparatus and show therapeutic pitfalls of multidisciplinary care.